Wednesday, April 24, 2024
HomeFunding CA-based Vasa Therapeutics Secures a Seed Funding

[Funding alert] CA-based Vasa Therapeutics Secures a Seed Funding

CA-based Vasa Therapeutics secures a seed funding. Orphinic Scientific SA ("Orphinic"), an early-stage investor that focuses on businesses with the potential to change the game, led this round. NuFund Venture Group, SeedFolio, and other private investment funds participated in the round as well.

CA-based Vasa Therapeutics secures a seed funding. Orphinic Scientific SA (“Orphinic”), an early-stage investor that focuses on businesses with the potential to change the game, led this round. NuFund Venture Group, SeedFolio, and other private investment funds participated in the round as well.

Read also – CA-based Hyperlink Ventures Secures it’s First fund at $32M

Artur Plonowski, MD, PhD, CEO and Co-founder of Vasa said, “We are delighted to gain support from a high-quality group of US and international investors who share Vasa’s mission to develop transformative therapies for cardiovascular aging that could extend the healthy lifespan, This closing comes at an exciting time for Vasa as VS-041, our clinical candidate for heart failure with preserved ejection fraction (HFpEF), enters the final stages of preclinical development with favorable FDA feedback at a recent pre-IND meeting.”

Adam Kruszewski, CEO of Orphinic said, “We are excited to have led the seed financing for Vasa. The company’s novel biomarker strategy can lead to a personalized medicine-based therapy for HFpEF, a highly heterogenous disease, for which the currently available drugs do not provide durable improvement, We are also pleased to see multiple opportunities for the other Vasa assets, including sarcopenia, obesity, and peripheral artery disease.”

About Vasa Therapeutics

Vasa Therapeutics , The privately held biopharmaceutical company Vasa is creating drugs that target the pathophysiology of cardiovascular ageing. VS-041 is the first possible HFpEF treatment based on personalised medicine. In a preclinical HFpEF model, VS-041 significantly reduces cardiac fibrosis and prevents the release of signalling collagen fragments.

Read also – ME-based Biochar Producer Standard Biocarbon Secures $5M in Funding

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular